Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul 17:8:42.
doi: 10.1186/1472-6882-8-42.

Clinically relevant safety issues associated with St. John's wort product labels

Kevin A Clauson  1 , Marile L Santamarina, Jennifer C Rutledge
Affiliations

Clinically relevant safety issues associated with St. John's wort product labels

Kevin A Clauson et al. BMC Complement Altern Med. .

Abstract

Background: St. John's wort (SJW), used to treat depression, is popular in the USA, Canada, and parts of Europe. However, there are documented interactions between SJW and prescription medications including warfarin, cyclosporine, indinavir, and oral contraceptives. One source of information about these safety considerations is the product label. The aim of this study was to evaluate the clinically relevant safety information included on labeling in a nationally representative sample of SJW products from the USA.

Methods: Eight clinically relevant safety issues were identified: drug interactions (SJW-HIV medications, SJW-immunosupressants, SJW-oral contraceptives, and SJW-warfarin), contraindications (bipolar disorder), therapeutic duplication (antidepressants), and general considerations (phototoxicity and advice to consult a healthcare professional (HCP)). A list of SJW products was identified to assess their labels. Percentages and totals were used to present findings.

Results: Of the seventy-four products evaluated, no product label provided information for all 8 evaluation criteria. Three products (4.1%) provided information on 7 of the 8 criteria. Four products provided no safety information whatsoever. Percentage of products with label information was: SJW-HIV (8.1%), SJW-immunosupressants (5.4%), SJW-OCPs (8.1%), SJW-warfarin (5.4%), bipolar (1.4%), antidepressants (23.0%), phototoxicity (51.4%), and consult HCP (87.8%). Other safety-related information on labels included warnings about pregnancy (74.3%), lactation (64.9%), discontinue if adverse reaction (23.0%), and not for use in patients under 18 years old (13.5%). The average number of a priori safety issues included on a product label was 1.91 (range 0-8) for 23.9% completeness.

Conclusion: The vast majority of SJW products fail to adequately address clinically relevant safety issues on their labeling. A few products do provide an acceptable amount of information on clinically relevant safety issues which could enhance the quality of counseling by HCPs and health store clerks. HCPs and consumers may benefit if the FDA re-examined labeling requirements for dietary supplements.

PubMed Disclaimer

References

    1. Nutrition Business Journal http://www.nutritionbusiness.com (accessed February 17, 2008)
    1. Natural Medicines Comprehensive Database http://www.naturaldatabase.com (accessed February 17, 2008).
    1. Natural Standard http://www.naturalstandard.com (accessed February 17, 2008)
    1. Charrois TL, Hill RH, Vu D, Foster BC, Boon HS, Cramer K, Vohra S. Community identification of natural health product-drug interactions. Ann Pharmacother. 2007;41:1124–9. doi: 10.1345/aph.1H463. - DOI - PubMed
    1. Ufer M, Meyer SA, Junge O, Selke G, Volz HP, Hedderich J, Gleiter CH. Patterns and prevalence of antidepressant use in the German state of Baden-Wuerttemberg: a prescription-based analysis. Pharmacoepidemiol Drug Saf. 2007:1153–60. doi: 10.1002/pds.1405. - DOI - PubMed